Michael S. Grimley, MD
- Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- michael.grimley@cchmc.org
- Board Certified
About
Biography
I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.
Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.
As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.
My research involves finding treatments for and prevention of viral infections in immunocompromised patients.
When I’m not treating patients or involved in research, I enjoy spending time with my family.
MD: Emory University School of Medicine, Atlanta, GA, 1992.
Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.
Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.
Certification: General Pediatrics, Pediatric Hematology/Oncology.
Licenses: Ohio, Texas.
Interests
Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia
Services and Specialties
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. The Journal of Infectious Diseases. 2025; 231:e123-e131.
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplantation and Cellular Therapy. 2025; 31:109.e1-109.e13.
633. Incidence and Outcomes of Pediatric Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients Under Surveillance and Not Under Surveillance for Human Adenovirus (HAdV) in the Post-HCT Period. Open Forum Infectious Diseases. 2025; 12:ofae631.198.
P-103. Adenoviremia Clearance Following Treatment with Intravenous (IV) Brincidofovir (BCV) in Immunocompromised Patients is Associated with Positive Clinical Disease Response: Preliminary Outcomes from the ATHENA Phase IIa Study. Open Forum Infectious Diseases. 2025; 12:ofae631.310.
Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘). Blood. 2024; 144:3516.
Prophylactic VSTs: a promising start but still work to do. Blood Advances. 2024; 8:4738-4739.
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. American Journal of Transplantation. 2024; 24:1634-1643.
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD. Bone Marrow Transplantation. 2024; 59:680-687.
Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients. Blood Advances. 2024; 8:1880-1892.
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica: the hematology journal. 2024; 109:1137-1148.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey